Trump announces trade deal with EU following months of negotiations
Twist Bioscience Corp (NASDAQ:TWST) CEO Emily Leproust recently sold a portion of her holdings in the company, according to a filing with the Securities and Exchange Commission. The sale, which took place on February 3, 2025, involved 5,200 shares of common stock at an average price of $49.352 per share, totaling approximately $256,630. The transaction comes as TWST shares have shown strong momentum, delivering a 43% return over the past year and trading near their 52-week high of $60.90. According to InvestingPro analysis, the stock appears to be trading above its Fair Value.
Following the transaction, Leproust retains ownership of 667,318 shares in the company. The shares sold were part of a "sell to cover" transaction to meet tax withholding obligations related to the vesting of restricted stock units, as mandated by Twist Bioscience’s equity incentive plans. These transactions are not discretionary trades by the reporting person. The company maintains a healthy financial position with a current ratio of 4.96, indicating strong liquidity to meet short-term obligations.
Twist Bioscience, a company based in South San Francisco, California, operates in the biological products sector, focusing on DNA synthesis for various applications in health care, agriculture, and industrial chemicals. While the company’s revenue grew by 26% in the last twelve months, analysts expect continued growth but do not anticipate profitability this year. Get deeper insights into TWST’s growth prospects and 8 additional key ProTips with an InvestingPro subscription.
In other recent news, Twist Bioscience has been the focus of several analysts’ upgrades and revised price targets. Scotiabank (TSX:BNS) analyst Sung Ji Nam raised the company’s price target to $62 from $54, following Twist Bioscience’s Q1 fiscal year 2025 financial results, which surpassed consensus predictions and previously issued company guidance. The company’s gross margins for the quarter exceeded the full year’s prior gross margin guidance, and its full-year fiscal 2025 guidance was revised upward, predicting total revenue growth of 19-21% year-over-year.
Meanwhile, Barclays (LON:BARC) analyst Luke Sergott increased the price target on Twist Bioscience shares to $58 from $52, citing the company’s growing momentum in its Express portfolio and Next-Generation Sequencing (NGS) tools. Twist Bioscience’s strategic focus on its core portfolio and cost-effective management of investments were highlighted as key strengths.
Baird maintained an Outperform rating and a $48 price target for Twist Bioscience, highlighting the consistent pricing premiums for the company’s Express Genes service. TD Cowen also maintained its Buy rating and a price target of $58 based on the company’s solid financial guidance for fiscal year 2025.
These recent developments reflect the positive market sentiment towards Twist Bioscience’s financial performance and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.